These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 31977410)

  • 1. Descovy Approved for HIV Prexposure Prophylaxis.
    Aschenbrenner DS
    Am J Nurs; 2020 Feb; 120(2):20. PubMed ID: 31977410
    [No Abstract]   [Full Text] [Related]  

  • 2. Emtricitabine/tenofovir alafenamide (Descovy) for HIV.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):100-1. PubMed ID: 27466750
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet.
    Wang X; Nutland W; Brady M; Green I; Boffito M; McClure M
    Int J STD AIDS; 2019 Jul; 30(8):765-768. PubMed ID: 31072205
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on HIV prevention and preexposure prophylaxis.
    Baker J; Rolls J
    JAAPA; 2020 Jun; 33(6):12-17. PubMed ID: 32384293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.
    Girometti N; Jones R; Levy J; McCormack S; Sullivan A; Barber TJ
    AIDS; 2016 Aug; 30(13):2131-3. PubMed ID: 27219131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis.
    Van Slyke L; Scott M
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760846. PubMed ID: 29534653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological properties and clinical findings of new drugs for the treatment of HIV-1, FTC/TAF 200/10 and 200/25 mg (Descovy
    Nakamoto H; Yamada H; Watanabe Y
    Nihon Yakurigaku Zasshi; 2017; 150(5):251-260. PubMed ID: 29118289
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhanced HIV viral load suppression with crushed combination tablets containing tenofovir alafenamide and emtricitabine.
    Fulco PP; Higginson RT
    Am J Health Syst Pharm; 2018 May; 75(10):594-595. PubMed ID: 29748295
    [No Abstract]   [Full Text] [Related]  

  • 10. Cluster headache-like symptoms during treatment with tenofovir disoproxil fumarate and emtricitabine.
    Citerne Q; Boyer L; Moreau E; Garon J; Gillet P; Petitpain N
    AIDS; 2019 Jul; 33(9):1535-1536. PubMed ID: 31259768
    [No Abstract]   [Full Text] [Related]  

  • 11. Symfi, Symfi Lo, and Cimduo for HIV.
    Med Lett Drugs Ther; 2019 Jan; 61(1563):e8-e10. PubMed ID: 30681663
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
    Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
    Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent FDA approvals and changes.
    AIDS Patient Care STDS; 2010 Feb; 24(2):133-4. PubMed ID: 20156092
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA paves the way for pre-exposure HIV prophylaxis.
    Holmes D
    Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
    [No Abstract]   [Full Text] [Related]  

  • 15. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New PrEP formulation approved…but only for some.
    The Lancet Hiv
    Lancet HIV; 2019 Nov; 6(11):e723. PubMed ID: 31672278
    [No Abstract]   [Full Text] [Related]  

  • 17. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men.
    McAllister JW; Towns JM; Mcnulty A; Pierce AB; Foster R; Richardson R; Carr A
    AIDS; 2017 Jun; 31(9):1291-1295. PubMed ID: 28301425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Association between Antiretroviral Therapy and Drug-Induced Immune Thrombocytopenia Purpura.
    Howard MD; Sim S
    Acta Haematol; 2019; 141(3):199-200. PubMed ID: 30840965
    [No Abstract]   [Full Text] [Related]  

  • 19. Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(6):520. PubMed ID: 26977839
    [No Abstract]   [Full Text] [Related]  

  • 20. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.